Xilio Therapeutics
35 hedge funds and large institutions have $16.3M invested in Xilio Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding
Funds holding: 35 → 35 (0)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.93% less ownership
Funds ownership: 4.04% → 3.11% (-0.93%)
34% less capital invested
Capital invested by funds: $24.7M → $16.3M (-$8.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$209K |
| 2 |
Morgan Stanley
New York
|
+$139K |
| 3 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
+$135K |
| 4 |
Two Sigma Investments
New York
|
+$65.8K |
| 5 |
Millennium Management
New York
|
+$45.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.87M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$459K |
| 3 |
Fidelity International
Hamilton,
Bermuda
|
-$209K |
| 4 |
Renaissance Technologies
New York
|
-$107K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$79.8K |
XLO Hedge Fund Activity: Q1 2025 in Review
35 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2025, worth a combined $16.3M — down 34% from $24.7M a quarter earlier.
Fund positioning in XLO was balanced in Q1 2025: 6 funds opened new positions, 6 closed out, 8 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $209K. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $2.87M sold.
- 35 institutional investors held Xilio Therapeutics (XLO) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $16.3M of Xilio Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
- 6 funds opened new Xilio Therapeutics positions in Q1 2025 and 6 closed out, a net change of 0 holders.
- The largest Xilio Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $209K added.
- The largest Xilio Therapeutics seller in Q1 2025 was Rock Springs Capital Management, an estimated $2.87M sold.
Based on aggregated 13F filings for Q1 2025.